A 5% holder can request an EGM, I believe.

First 21 Last

Share
Profile

Follow
cafa

8,917 Posts.

32

15/12/16

14:42

Post #: 21364307
Share

Originally posted by craft ↑

"If the answer to question 1 is “yes”, when did SRX first become aware of the decrease in anticipated dose sales growth for FY17, as disclosed in the Update Announcement?"

The restatement of the question by SRX in the response to totally ignore the requirements of listing rule 3.1

"Given the fact that what is involved is a prediction of future results rather than
a reflection of past results, it is not so much a question of when SRX first became
aware of the decrease in anticipated dose sales growth for FY17, but rather a
question of when, having regard to the information then available."

Listing Rule 3.1, which requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity’s securities.

The definition of “aware” in Chapter 19 of the Listing Rules, which states that:
“an entity becomes aware of information if, and as soon as, an officer of the entity (or, in the
case of a trust, an officer of the responsible entity) has, or ought reasonably to have, come into possession of the information in the course of the performance of their duties as an officer of that entity”

It is impossible in my view that even if GW didn’t know the actual sales numbers that he should at least “ought reasonably” to have been aware of sales information and that it was tracking below forecast. Even if sales were on target and then stopped dead, mathematically he must have been aware sometime ago that sales would not meet forecast. The actual daily numbers which could be subpoenaed would reveal all.

Then we have GW share sales to compound the lack of timely disclosure which it would seem amounts to insider trading if he had the sales data or incomprehensible CEO incompetence if he didn’t. The question is was the board complicit?

Yes GW had sold shares for Tax purposes in the past and yes it is good risk management to sell at the time of vesting because that is when the tax liability arises. The past practice was to sell at the time of vesting which makes total sense, but this time the nexus in timing was broken – why? He opened himself to timing risk like the rest of us. 114,968 shares vested on 29/7 and with a market close on that day his tax liability would be about 1.8M. He sold 2.1M of stock on 26/10 and said it was to cover tax. Unlike us he had inside sales data information when making his sale.

If he did not sell, his entire vesting of shares would now be currently worth about the amount of his tax liability. It was said in the announcement that the chair was aware of his intentions to sell for tax reasons, but was the board complicit in letting him do it before the sales data came to light so as to not have the incentive payment not entirely eaten by the tax liability if he sold afterwards or did GW withhold the information he ought to have know and inform the board of?

When the nexus of vesting date and selling to fund tax obligations was broken – GW opened himself to timing risk and he is in breach of the law if he used insider information to reduce that timing risk.

Now add that the ASX received a tip-off and GS has acted in the market in the time frame of the tip off.

We have a dead board/CEO walking. If they don’t take each other out trying to preserve their own skins, or get taken out by legal action – we must act as Shareholders. After this ASX query and the totally unacceptable response to it there is no way this is an acceptable board to leave our company in the hands of.

Expand

A 5% holder can request an EGM, I believe.

SRX Price at posting: $16.49 Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

The iron ore comeback: Can it last?

HAS

Hastings progressing Yangibana to production with lower costs

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ZNC

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

There are more pages in this discussion • 85 more messages in this thread...

First 21 Last

Add SRX (ASX) to my watchlist

(20min delay)
Last 17.5¢		Change -0.003(1.41%)		Mkt cap ! $75.62M

Open	High	Low	Value	Volume
17.5¢	17.8¢	17.5¢	$4.968K	28.32K

Buyers (Bids)

No.	Vol.	Price($)
8	5792335	17.5¢

Sellers (Offers)

Price($)	Vol.	No.
18.0¢	265720	27

View Market Depth

No.	Vol.	Price($)
8	5792335	0.175
2	200000	0.170
3	218187	0.165
1	100000	0.160
1	2577	0.097

Price($)	Vol.	No.
0.180	265720	27
0.185	278850	12
0.190	19026	4
0.195	35000	2
0.200	246193	2

Last trade - 15.20pm 30/09/2024 (20 minute delay)

SRX (ASX) Chart

A 5% holder can request an EGM, I believe.

The iron ore comeback: Can it last?

Hastings progressing Yangibana to production with lower costs

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

A 5% holder can request an EGM, I believe.

Top Stories

The iron ore comeback: Can it last?

Hastings progressing Yangibana to production with lower costs

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News